News & stories

News | Sep 12, 2023

J&J and Cepheid must expand access to TB drug and tests

TB is curable but remains the world’s leading infectious disease killer as pharma corporations stand in the way of affordable medical tools

News | Aug 24, 2023

MSF closes medical operations in Tripoli, Libya

Tripoli has become an increasingly challenging environment for international organizations.

News | Jul 18, 2023

J&J must withdraw extended patents on lifesaving TB drug

Recent deal offering controlled generics access in limited countries does not go far enough

News | May 26, 2023

MSF welcomes World Health Assembly resolution on disease testing

Governments must now implement the resolution and make sure diagnostic tools are widely affordable and accessible

News | Apr 26, 2023

J&J must stop blocking generic versions of lifesaving TB drug

J&J’s patent monopoly continues to keep bedaquiline out of reach.

News | Mar 23, 2023

MSF applauds rejection of J&J attempt to extend TB drug patent

The rejection of the salt form of bedaquiline is welcome news for people with drug-resistant tuberculosis.

News | Mar 22, 2023

World TB Day: More people need access to testing and treatment

MSF calls on governments and donors to speed up access to new, improved treatment for drug-resistant tuberculosis.

News | Dec 21, 2022

MSF trial finds better treatment for people with TB

Results published in the New England Journal of Medicine today show that a much shorter treatment regimen for drug-resistant TB is safer and cured almost 90 percent of patients

News | Dec 15, 2022

WHO recommends TB regimen found effective by MSF clinical trial

News | Nov 08, 2022

MSF: Opportunity to increase access to newer, safer TB drugs is at risk

With newer TB drugs set to go off patent in 2023, drugmakers J&J, Otsuka, and TB Alliance must remove additional barriers that block more affordable versions from entering the market.